Caris Life Sciences Presented Research Demonstrating the Value of Whole Transcriptome Sequencing in Precision Oncology at the Association of Molecular Pathology 2026 Annual Meeting
Caris Life Sciences, Inc. 2026 Q3 - Results - Earnings Call Presentation
Piper Sandler Maintains Neutral on Caris Life Sciences, Raises Price Target to $25
Caris Life Sciences Publishes Study Highlighting the Value of Comprehensive Molecular Profiling in Characterizing ESR1-Mutated Metastatic Breast Cancer
Caris Life Sciences Inc (CAI) Q3 2026 Earnings Call Highlights: Record Revenue, Sixth Straight ...
Citigroup Maintains Buy on Caris Life Sciences, Raises Price Target to $36
TD Cowen Maintains Buy on Caris Life Sciences, Raises Price Target to $38
Caris Life (CAI) Q3 2026 Earnings Call Transcript
14% Below Fair Value? Caris Life Sciences (CAI) On Raised 2026 Guidance
BTIG Reiterates Buy on Caris Life Sciences, Maintains $38 Price Target
Caris Life Sciences Q3 Earnings Call Highlights
Caris Life Sciences (NASDAQ:CAI) Slides After Q3 Beat as Valuation Expectations Reset
Caris Life Sciences, Inc. (CAI) Q3 2026 Earnings Call Transcript
Caris Life Sciences Reports Third Quarter 2026 Financial Results and Increases 2026 Revenue Guidance
Caris Life Sciences Q3 2026 Earnings Call Transcript
Caris Life Sciences Raises FY2026 Sales Guidance from $1.030B-$1.040B to $1.040B-$1.050B vs $1.030B Est
Caris Life Sciences Q3 EPS $0.05 Beats $0.04 Estimate, Sales $275.358M Beat $255.363M Estimate
Analysts Estimate Caris Life Sciences,?Inc. (CAI) to Report a Decline in Earnings: What to Look Out for
BTIG Maintains Buy on Caris Life Sciences, Raises Price Target to $38
Caris Life Sciences Launches New National Commercial Featuring Jordan Spieth Highlighting the Power of Artificial Intelligence in Early Stage Cancer Detection
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.